ADMA - Latest News
ADMA Biologics, Inc. (ADMA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $2.03B. Trailing twelve-month P/E ratio is 12.49. Beta to the broader market is 0.73.
The article list below shows the most recent ADMA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ADMA Headlines
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
globenewswire.com - Jul 1, 2026
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologic
ADMA Lawsuit Notification: ADMA Biologics Investors Bring Securities Class Action Following Channel Stuffing Allegations – Contact BFA Law by August 10 Deadline
globenewswire.com - Jul 1, 2026
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been fil
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
globenewswire.com - Jun 30, 2026
NEW YORK and NEW ORLEANS, June 30, 2026 (GLOBE NEWSWIRE) -- Kahn Swick and Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Ch
ROSEN, LEADING TRIAL LAWYERS, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA
newsfilecorp.com - Jun 30, 2026
New York, New York--(Newsfile Corp. - June 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AD
ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
prnewswire.com - Jun 30, 2026
Did you buy ADMA securities between August 9, 2024 and March 25, 2026? Affected ADMA Investor Summary Who: ADMA Biologics, Inc.
How News Affects ADMA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ADMA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ADMA news questions
- What is the latest ADMA news headline?
- The most recent ADMA headline (Jul 1, 2026) is "INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ADMA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ADMA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ADMA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.